NCT06833320
Propranolol Treatment for Postoperative Chylothorax
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment resumed after suspension Show 4 more changesShow less
- Eligibility criteria expanded, about 29 words
- Primary endpoints: details revised at 1 of 7 entries
- Study description revised
- Site details revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Administrative changes
- Site details revised
- Minor Study site revisedv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 2025 to Sep 9, 2025
- Site details revised
- Notable Start date: Jun 2025 to Sep 2025v3
- Notable Start date: Mar 1, 2025 to Jun 2025
- Secondary endpoints: details revised at 1 of 16 entries
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Daily heart rates recorded in flow chart and 1 hour after each dose
Timeframe: 24 days
Daily blood pressures recorded in flow chart and 1 hour after each dose
Timeframe: 24 days
Daily glucose levels
Timeframe: 24 days
Expected and unexpected AEs, per patient
Timeframe: 24 days
Days with documented chest tube (# days), CXR
Timeframe: 24 days
Initial volume of fluid drained (mL, mL/kg/day)
Timeframe: Day 0
Days hospitalized
Timeframe: 6 months
Secondary (16)
Thyroglobulin (TG) lymphocyte count
Pre-operative and post-operative echocardiogram anatomic findings for patients with 4-chamber hearts
Pre-operative and post-operative echocardiogram anatomic findings for patients with single ventricle (SV) physiology
Percent of patients with Type 1 anatomy
Percent of patients with Type 2 anatomy
Show 11 moreShow less
Percent of patients with Type 3 anatomy
Percent of patients with Type 4 anatomy
Serum albumin
White Blood Cell (WBC) count
C-Reactive Protein (CRP)
Immunoglobulin level
AT3 titer
Protein S titer
Protein C titer
Hours on bypass during CHD surgery
Triglyceride level in chylothorax fluid
Arms and interventions
PlaceboPlacebo comparator
Placebo suspension will only have Ora-Blend
Propranolol hydrochlorideActive comparator
Subjects will be randomized to receive 2mg/kg/day. Propranolol will be administered orally, either as a tablet or as a solution, in equal divided doses three times a day.
Drugs: Propranolol Hydrochloride, Placebo
Sites
1 site in 1 country
- Columbia University Irving Medical Center/NewYork-PresbyterianNew York, New York, United States